Close Menu

NEW YORK (GenomeWeb News) – Investment bank Barclays Capital today downgraded Life Technologies to an Equal Weight rating, citing the company's exposure to an anticipated soft academic and government funding environment and uncertainty about its sequencing portfolio.

In addition to downgrading Life Tech from an Overweight rating, Barclays also lowered the price target on the company's stock to $45 from $55; lowered 2011 EPS estimates to $3.71 from $3.73; and recalculated 2012 EPS estimates to $4.10 from $4.17.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.